Valeria L. Runza

Penzberg, BY 82377, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations.

End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations.

Journal: International journal of pharmaceutics: X

Published: September 30, 2022

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.

Journal: The Journal of experimental medicine

Published: August 11, 2017

A drug development perspective on targeting tumor-associated myeloid cells.

A drug development perspective on targeting tumor-associated myeloid cells.

Journal: The FEBS journal

Published: June 19, 2017

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Journal: Cancer cell

Published: October 12, 2016

Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model.

Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model.

Journal: PloS one

Published: March 04, 2016

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.

Journal: Oncotarget

Published: January 20, 2016

Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.

Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 02, 2015

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Journal: Cancer cell

Published: October 30, 2015

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Journal: Molecular cancer therapeutics

Published: August 11, 2015

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 21, 2014

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Journal: Cancer cell

Published: October 31, 2013

Immature mouse granulocytic myeloid cells are characterized by production of ficolin-B.

Immature mouse granulocytic myeloid cells are characterized by production of ficolin-B.

Journal: Molecular immunology

Published: June 19, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026